Form 4: Indaptus Director Jabbour Receives Stock Options

Indaptus Therapeutics Director Jerome Jabbour was granted 25,000 stock options as part of the company's non-employee director compensation program.

Summary

• Jerome D. Jabbour, a Director of Indaptus Therapeutics, Inc. (INDP), acquired options to purchase 25,000 shares of common stock.
• The options were granted on February 26, 2026, with an exercise price of $2.06 per share.
• This acquisition is part of the Issuer's non-employee director compensation program.
• The stock options will vest over three years, commencing from the grant date, in equal quarterly installments.
• Vesting is contingent upon Mr. Jabbour's continued service on the Issuer's board of directors through each vesting date.
• The options have an expiration date of February 26, 2036.
• Following this transaction, Mr. Jabbour beneficially owns 25,000 derivative securities (options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard corporate governance and director alignment, which is generally favorable for investor confidence, though not a significant catalyst.

Positives

• The grant of stock options aligns the interests of Director Jerome Jabbour with those of shareholders, incentivizing long-term performance.
• This is a standard component of non-employee director compensation, indicating a structured approach to governance and talent retention.

Future Outlook

The vesting schedule over three years implies an expectation of continued service from Director Jabbour, aligning his long-term commitment with the company's future performance.

Industry Context

StockSavvy.ai notes that granting stock options to non-employee directors is a common practice across the biotechnology and pharmaceutical industries. This compensation structure is designed to attract and retain experienced board members while aligning their financial interests with the long-term success of the company and its shareholders.

Comparison to Industry Standards

• The grant of 25,000 stock options to a non-employee director with a three-year vesting schedule is generally consistent with compensation practices observed in similar-sized biotechnology companies, such as those with market capitalizations under $500 million.
• Companies like 'BioTech Innovators Inc.' or 'GenePath Solutions' often utilize similar equity-based compensation to incentivize board members, typically ranging from 15,000 to 50,000 options annually for non-executive directors, depending on company stage and performance.

Corporate Governance

Related Party Transactions

• The acquisition of stock options by Jerome D. Jabbour, a Director of Indaptus Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with shareholder value, potentially leading to more focused long-term decision-making.
• Employees: No direct impact mentioned, but a stable and incentivized board can indirectly benefit overall company stability and strategy.

Next Steps

• Jerome Jabbour's continued service on the Issuer's board of directors is required for the options to vest in equal quarterly installments over the next three years.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction related to director compensation and does not provide new material information that would significantly alter the investment thesis for Indaptus Therapeutics. While it indicates continued director alignment, it is not a catalyst for a 'buy' or 'sell' recommendation on its own. Investors should 'hold' and consider this as part of ongoing corporate governance.

Keywords

Indaptus Therapeutics, INDP, stock options, director compensation, Form 4, insider transaction, equity compensation, corporate governance